![home_banner2](https://www.siroclinpharm.com/wp-content/uploads/2019/04/Drug-Safety.jpg)
Risk Management
End to end services for various pharmacovigilance aggregate reports for more than a decade across all regions including US, EU, Japan, China and other APAC countries.
End to end services for various pharmacovigilance aggregate reports for more than a decade across all regions including US, EU, Japan, China and other APAC countries.
End to end services for various pharmacovigilance aggregate reports for more
than a decade across all regions including US, EU, Japan, China and other APAC countries.
Differentiators
![Global Pioneer](https://www.siroclinpharm.com/wp-content/uploads/2019/04/GLOBAL-PIONEER-IN-DSUR’S.png)
Global Pioneer in DSUR’s
First DSUR submitted by SIRO IN 2011, within 30 days of ICHE2F guideline implementation
Over 500 DSURs submitted with no queries from health authorities
![Risk Management](https://www.siroclinpharm.com/wp-content/uploads/2019/04/CORE-EXPERTS-IN-RISK-MANAGEMENT-PLAN.png)
Core experts in Risk Management Plan
Specialized team for EU and Core RMP to leverage efficiencies in authoring, technical review and QC for all types of regulatory submissions
![Dedicated Experts](https://www.siroclinpharm.com/wp-content/uploads/2019/04/DEDICATED-EXPERTS-ACROSS-ALL-TA’S.png)
Dedicated experts across all major Therapeutic Areas
Proficient across all major Therapeutic Areas, scientific review of aggregate reports by team of specialized physicians
![Reference Tools](https://www.siroclinpharm.com/wp-content/uploads/2019/04/REFERENCE-TOOLS.png)
Innovation
Day minus 90 implementation of aggregate reports
Experience in SOP and template development for various safety reports adhering to regulatory guidelines
Document Types
![Drug Safety and Risk Management](https://www.siroclinpharm.com/wp-content/uploads/2019/04/Drug-Safety-and-Risk-Management-website-content-1.png)